New Scientific Review Highlights Potential of CBD in Treating Cancer, COVID Pain
A recently conducted scientific review has called attention to CBD’s potential in managing and treating symptoms of conditions such as diabetes, pain, epilepsy, schizophrenia, COVID-19 and cancer, among others. The review tries to summarize the impact of marijuana on human health, noting that the plant and its compounds demonstrate anti-inflammatory, neuroprotective, antibacterial, antithrombotic, antiepileptic and analgesic properties.
Through funding from the National Product Institute of Science and Technology, the study also examined recent research advancements on CBD, focusing on possible medical applications. The review was carried out by an eight-person team from South Korea, representing the National Product Institute of Science & Technology, the Gyeongbuk Institute for Bioindustry, Chung-Ang University and Gachon University.
The review features different sections, including one that focuses on cannabinoids as a treatment of Dravet syndrome, a form of epilepsy, and one focused on CBD’s effect on biological processes related to diabetes. A separate section focuses on the use of cannabinoids to manage schizophrenia symptoms while another centers on cannabinoids as potential coronavirus infection inhibitors.
In their report, the researchers acknowledged CBD’s industrial applications, which include paper, fuel, clothing, skin-care products, massage oil and pharmaceutical drugs.
While most of the review’s discoveries are familiar to those interested in research on marijuana, drug laws in South Korea remain among the strictest globally. The country partially legalized medical marijuana in 2018, but CBD and recreational cannabis remain prohibited”.
The review’s findings were reported in the “Applied Biological Chemistry” journal.
Meanwhile, in the United States, the federal government has delved into research on hemp and its regulation since the crop and its products were legalized through the 2018 Farm Bill. For instance, the federal department of agriculture has started working more closely with hemp cultivators and breeders. In 2023, it released updated guidelines on how to pick out, describe and evaluate different plant varieties of hemp.
In March 2024, the same department revealed that a genetically modified hemp version developed by Wisconsin investigators could safely be grown and bred in the U.S. The department explained that this hemp version, Badger G, didn’t produce CBD or THC but did have higher CBG levels.
For its part, the U.S. Food and Drug Administration is currently considering an initiative that would allow hemp seed meal to be used as livestock for chickens.
Stakeholders and legislators are also considering some proposals that may be included in the new farm legislation, including proposals to allow hemp businesses to market products such as CBD legally as dietary supplements. Entities such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) could have more products to offer once federal regulations clarify that CBD can be sold as a dietary supplement.
NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer
A recently conducted scientific review has called attention to CBD’s potential in managing and treating symptoms of conditions such as diabetes, pain, epilepsy, schizophrenia, COVID-19 and cancer, among others. The review tries to summarize the impact of marijuana on human health, noting that the plant and its compounds demonstrate anti-inflammatory, neuroprotective, antibacterial, antithrombotic, antiepileptic and analgesic properties.
Through funding from the National Product Institute of Science and Technology, the study also examined recent research advancements on CBD, focusing on possible medical applications. The review was carried out by an eight-person team from South Korea, representing the National Product Institute of Science & Technology, the Gyeongbuk Institute for Bioindustry, Chung-Ang University and Gachon University.
The review features different sections, including one that focuses on cannabinoids as a treatment of Dravet syndrome, a form of epilepsy, and one focused on CBD’s effect on biological processes related to diabetes. A separate section focuses on the use of cannabinoids to manage schizophrenia symptoms while another centers on cannabinoids as potential coronavirus infection inhibitors.
In their report, the researchers acknowledged CBD’s industrial applications, which include paper, fuel, clothing, skin-care products, massage oil and pharmaceutical drugs.
While most of the review’s discoveries are familiar to those interested in research on marijuana, drug laws in South Korea remain among the strictest globally. The country partially legalized medical marijuana in 2018, but CBD and recreational cannabis remain prohibited”.
The review’s findings were reported in the “Applied Biological Chemistry” journal.
Meanwhile, in the United States, the federal government has delved into research on hemp and its regulation since the crop and its products were legalized through the 2018 Farm Bill. For instance, the federal department of agriculture has started working more closely with hemp cultivators and breeders. In 2023, it released updated guidelines on how to pick out, describe and evaluate different plant varieties of hemp.
In March 2024, the same department revealed that a genetically modified hemp version developed by Wisconsin investigators could safely be grown and bred in the U.S. The department explained that this hemp version, Badger G, didn’t produce CBD or THC but did have higher CBG levels.
For its part, the U.S. Food and Drug Administration is currently considering an initiative that would allow hemp seed meal to be used as livestock for chickens.
Stakeholders and legislators are also considering some proposals that may be included in the new farm legislation, including proposals to allow hemp businesses to market products such as CBD legally as dietary supplements. Entities such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) could have more products to offer once federal regulations clarify that CBD can be sold as a dietary supplement.
NOTE TO INVESTORS: The latest news and updates relating to Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) are available in the company’s newsroom at https://cnw.fm/SFWJ
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer
